Together, our as well as others’ data demonstrate that SMARCA5 is a valuable epigenetic target suitable for inhibitor discovery projects and subsequent validation in MDS/AML and potentially also in other types of cancer. The gene discussed is SMARCA5; the disease is myelodysplastic syndrome.